Results 281 to 290 of about 117,830 (339)

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This cohort study of 1793 atopic dermatitis patients (aged ≥ 12) found higher infection rates with Janus kinase inhibitor treatment compared to biologic treatment, particularly for herpes infections, with a history of viral or fungal skin infection as a risk factor associated with infection.
Lian F. van der Gang   +22 more
wiley   +1 more source

Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Delgocitinib cream demonstrated minimal systemic exposure and no significant accumulation over time in patients with moderate to severe CHE. The systemic exposure was significantly lower versus oral administration (relative bioavailability: 0.6%). These findings suggest that no systemic pharmacological effect is expected with topical application of ...
Diamant Thaçi   +5 more
wiley   +1 more source

Long‐Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real‐World Multicentric Case Series

open access: yes
International Journal of Dermatology, EarlyView.
Christine Bangert   +4 more
wiley   +1 more source

Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Optimal treatment for frontal fibrosing alopecia (FFA) remains contentious. An international expert panel agreed that highly/ultra‐potent topical steroids were the preferred first‐line topical therapy. Preferred systemic therapies were 5‐alpha reductase inhibitors, followed by hydroxychloroquine.
Nekma Meah   +64 more
wiley   +1 more source

Home - About - Disclaimer - Privacy